Key Highlights
- Shares of Co-Diagnostics (CODX) advanced 9.43% to reach $2.90 during Friday’s premarket session
- CoSara Diagnostics, the firm’s Indian joint venture, secured an agreement for market entry into Bangladesh, Pakistan, Nepal, and Sri Lanka
- This territorial addition brings CoSara’s estimated South Asian addressable market to approximately $13 billion
- The expansion will focus on distributing the PCR Pro® point-of-care system and SARAGENE® diagnostic products, contingent on regulatory clearances
- A virtual distributor briefing is scheduled for Q2 2026, with an in-person training conference planned for later in the summer
Shares of Co-Diagnostics (CODX) advanced 9.43% to $2.90 in Friday’s premarket session following news of a significant geographic expansion by the company’s Indian joint venture operation.
CoSara Diagnostics Pvt. Ltd., formed through a partnership between Co-Dx and Ambalal Sarabhai Enterprises Limited (ASE Group), has finalized an agreement extending its commercial operations and distribution network throughout South Asia. The agreement covers four additional territories: Bangladesh, Pakistan, Nepal, and Sri Lanka.
According to the company’s internal research combined with external market intelligence, this geographic expansion increases CoSara’s total addressable market within the region to an estimated $13 billion.
The territorial agreement aims to facilitate the commercial rollout of two primary product lines: the CoSara PCR Pro® point-of-care diagnostic instrument and the SARAGENE® testing portfolio. Market entry in each territory remains dependent on securing appropriate regulatory authorizations.
CoSara is actively working to build distribution infrastructure throughout the four newly added countries. This groundwork includes navigating regulatory requirements, pinpointing priority customer groups, and forming partnerships with regional distribution networks.
Executive Perspectives on Regional Growth
Mohal Sarabhai, Chief Executive Officer of CoSara, emphasized that South Asia represents a significant and expanding opportunity for convenient, non-invasive molecular diagnostic solutions. He highlighted tuberculosis screening, HPV detection, and respiratory pathogen testing as particularly important application areas.
Dwight Egan, CEO of Co-Diagnostics, characterized the agreement as aligned with the company’s broader infrastructure-focused expansion approach. The strategy emphasizes establishing local manufacturing capabilities and distribution networks ahead of commercial launches — a framework being implemented across the United States, South Asia, and the MENA region.
Egan indicated that this approach is designed to enable Co-Dx to achieve scalable international deployment of its PCR point-of-care technology platform.
To facilitate distributor recruitment and engagement, CoSara has scheduled a virtual information and training session during the second quarter of 2026. A comprehensive in-person distributor conference and training program will follow during the summer months.
Current Stock Performance Context
Prior to Friday’s premarket rally, CODX had been trading in proximity to its 52-week low of $2.04. The 9.43% premarket gain elevated the stock to $2.90.
Investors should note that the PCR Pro® instrument and associated platform technologies remain under FDA review and have not yet received commercial clearance for sale.
In recent corporate developments, Co-Diagnostics announced in March that it had secured patent protection in Japan for its PCR platform technology. Previously, the company successfully regained compliance with NASDAQ listing requirements following a period of concern regarding its continued eligibility.
The company’s $13 billion total addressable market projection relies on internal analysis supplemented by third-party market research. Ultimate revenue generation will depend on the timing of regulatory approvals and the effectiveness of distributor network development across all four newly targeted markets.
